Drug maker stays close to doctors and patients
New York Times, March 17, 2008
Peter A. Kouides, MD, a hematologist at Rochester (NY) General Hospital, said he once had a patient with Gaucher disease who declined to be treated with a drug made by Genzyme. For years, Genzyme's representatives were always asking the hospital about why they were not treating the patient, he says. While most pharmaceutical makers do not even know the identities of most of the people taking their drugs, Genzyme knows virtually everyone with Gaucher disease. As a result, some critics say Genzyme influences treatment to an unusual extent and encourages the use of high doses of its drug.
- 'Kafkaesque' Value System Unfairly Penalizes Doctor Pay
- mHealth Tackles Readmissions
- Proton Beam Therapy Poised for Growth in US
- CNO Leads $1M Charge for New Scrubs, Uniforms
- Targeting Self-Insured Populations
- MA an Insurance Proving Ground for Providers
- Some Cancer Hospitals' Quality Data Will Soon Be Public
- 4 Crucial Tactics for Reining in Healthcare Cost
- How Digital Strategy Shapes Patient Engagement at Boston Children's Hospital
- Docs Fret as HHS Addresses Malpractice Reporting 'Loopholes'